BASF increases prices for pharmaceutical excipients and active ingredients

BASF increases prices for pharmaceutical excipients and active ingredients
2011-08-29
P-11-392
Effective September 1, 2011, BASF will increase the sales prices globally for all pharmaceutical excipients and generic active pharmaceutical ingredients by 10%. 
 

This price increase affects the entire excipients portfolio including all binders, disintegrants, coatings, solubilizers, and solvents. The affected generic active pharmaceutical ingredient (API) portfolio contains products like Ibuprofen, Caffeine, and Pseudoephedrine.

 

Due to the continued rise in costs for raw materials, energy and labor this price increase has become necessary. All existing contractual obligations will be honored.

 

About BASF's Pharma Ingredients & Services

BASF produces and markets a broad range of active ingredients and excipients, as well as exclusive synthesis services for the pharmaceutical industry. These products are made using the latest technologies, to the highest quality standards and in compliance with cGMP guidelines. Further information can be found at www.pharmaingredients.basf.com.

 

About BASF

BASF is the world's leading chemical company: The Chemical Company. Its portfolio ranges from chemicals, plastics, performance products, and agricultural products to oil and gas. As a reliable partner BASF creates chemistry to help its customers in virtually all industries to be more successful. With its high-value products and intelligent solutions, BASF plays an important role in finding answers to global challenges such as climate protection, energy efficiency, nutrition and mobility. BASF posted sales of more than €63.9 billion in 2010 and had approximately 109,000 employees as of the end of the year. Further information on BASF is available on the Internet at www.basf.com or in the Social Media Newsroom at www.newsroom.basf.com.

 

Suggested Articles

The Trump administration has selected five COVID-19 vaccines for Operation Warp Speed, the NYT reports, with Big Pharma dominating the list.

Racing with some COVID-19 vaccine heavyweights, Novavax has brought on a partner to manufacture adjuvant for its in-development shot. 

Bristol Myers Squibb's Zeposia will leverage promising top-line phase 3 data into a possible FDA approval in the lucrative ulcerative colitis market.